Drug Profile
Belantamab mafodotin - GSK
Alternative Names: anti-BCMA-ADC - GSK ; Belamaf; belantamab mafodotin-blmf; blenrep; BLENREP; GSK'916; GSK-2857916; J6M0-mcMMAFLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Amgen; Atrium Health; GSK
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Plasmablastic lymphoma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II BelaRd trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Updated efficacy, adverse event and pharmacokinetics data from a phase II trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH-Hem-2023)